

# Swiss Re AG SWX:SREN

## FQ1 2020 Earnings Call Transcripts


**Thursday, April 30, 2020 12:00 PM GMT**

S&P Global Market Intelligence Estimates

	-FQ4 2019-	-FQ1 2020-	-FY 2019-	-FY 2020-
	CONSENSUS	CONSENSUS	CONSENSUS	CONSENSUS
EPS Normalized	-	-	4.35	5.08
Revenue (mm)	8231.49	9494.26	37064.80	41744.43

Currency: USD

Consensus as of Apr-30-2020 8:51 AM GMT



# Table of Contents

Call Participants	.....	3
Presentation	.....	4
Question and Answer	.....	7

# Call Participants

## EXECUTIVES

**Edouard Schmid**

*Group Chief Underwriting Officer &  
Member of Executive Committee*

**Guido Fürer**

*Group Chief Investment Officer &  
Member of Executive Committee*

**John Robert Dacey**

*Group CFO & Member of Executive  
Committee*

**Philippe Brahin**

*Head Investor Relations and Head  
Governmental Affairs & Sustainability*

## ANALYSTS

**Andrew James Ritchie**

*Autonomous Research LLP*

**Ivan Bokhmat**

*Barclays Bank PLC, Research Division*

**Jonathan Peter Phillip Urwin**

*UBS Investment Bank, Research  
Division*

**Paris Hadjiantonis**

*Exane BNP Paribas, Research Division*

**Thomas Fossard**

*HSBC, Research Division*

**Vikram Gandhi**

*Societe Generale Cross Asset  
Research*

**Vinit Malhotra**

*Mediobanca - Banca di credito  
finanziario S.p.A., Research Division*

# Presentation

## Operator

Good morning or good afternoon. Welcome to Swiss Re First Quarter 2020 Key Financial Data Conference Call. Please note that today's conference call is being recorded.

At this time, I would like to turn the conference over to John Dacey, CFO. Please go ahead, sir.

## John Robert Dacey

*Group CFO & Member of Executive Committee*

Thank you and good morning or good afternoon to everyone. I'm here today with Edi Schmid, our Chief Underwriting Officer; and Guido Furer, our Chief Investment Officer, who will provide some insights on the impact of COVID-19 on our underwriting and asset management operations. Also in the room is Philippe Brahini, our Head of Investor Relations.

I'd like to start with a brief overview of the key figures we published this morning. Swiss Re entered the pandemic crisis in a very strong capital position. We also took proactive measures to protect our investment portfolio in the balance sheet in particular, and Guido will tell you more about it. On the operational side, we are able to support our clients and partners without disruptions. And our activities remain resilient in the current environment as the quality of our eco renewals testifies.

Nonetheless, COVID-19 related claims weighed on our results. We reported net losses of \$225 million for the first quarter of 2020. P&C Reinsurance reported a net income of \$61 million, despite the losses related to COVID-19. The business segment was also affected by large natural catastrophe slightly above our expected losses, mainly related to weather events in Australia and winter storms in Europe. We also experienced some negative prior-year development, which somewhat unusually was driven more by premium interrupts than reserve additions. Excluding the burdens from COVID-19, P&C Re's normalized combined ratio is in line with our 97% estimate for the year.

Life & Health Reinsurance delivered above its target ROE, reflecting strong underwriting and investment results with no material underwriting impact in the quarter from COVID-19. Corporate Solutions reported a net loss of \$171 million (sic) [ \$167 million ], impacted by losses related to COVID-19. Excluding those losses, the combined ratio was 13 percentage points better than 1 year ago and the normalized combined ratio was broadly in line with our 105% estimate for the full year.

Life Capital results was impacted by the mark-to-market on our implied holding in Phoenix, partly offset by a hedge on the U.K. equity markets. The underlying business performed broadly as expected. The agreed sale of ReAssure remains on track and is expected to close in the third quarter of 2020. The group reported a strong return on investment of 3.2% for the first 3 months of 2020, as an active portfolio management and hedging significantly offset the impact of financial market volatility on the asset portfolio.

As for the April Reinsurance renewals, we are pleased with the outcome achieved. We saw overall volume growth of 4%, while nominal prices increased by 8%, with a strong increase on Japan windstorm of more than 50%. Risk-adjusted price quality year-to-date remained unchanged, reflecting the lower interest rate environment we're in and material adjustments to loss assumptions, particularly with respect to certain nat cat exposures.

Moving onto the balance sheets. Swiss Re maintains its industry-leading capital position with the group's Swiss Solvency Test ratio comfortably above 200% as of the 31st of March. As confirmed following our AGM on the 17th of April and in light of the current volatility in financial markets and global economic situations, the Board of Directors has concluded that the share buyback program will not be launched. We will continue to manage our assets in our capital with our utmost foresight allowing us to continue to support the clients and preserve value for shareholders in these difficult times.

And with this, I turn it over to Edi.

## Edouard Schmid

*Group Chief Underwriting Officer & Member of Executive Committee*

Thank you, John. And good morning and good afternoon from my side. As John already mentioned, our Q1 results were impacted by USD 476 million of COVID-19 claims. Of these, USD 253 million were in P&C Reinsurance and USD 223

million in Corporate Solutions. These reflects claims notifications as well as evidence of expected claims materialized as of end of March. Close to 75% of the Reinsurance loss and over 80% of the Corporate Solutions loss relates to event cancellation, with the remainder mostly coming from business interruption and smaller amounts from other lines including credit and surety.

As previously communicated, our total maximum exposure to event cancellation across 2020 is a mid-to high triple digit million amount. This is due toward the first half of the year in terms of events covered, which means you would expect to book most of the losses in the first 2 quarters. On credit and surety, we would expect further losses as the recession impact of the crisis becomes more visible in various economies. Economic development remains highly uncertain depending, for example, on the effectiveness of substantial government interventions.

P&C Re has a 10% market share in credit and surety, and Corporate Solutions less than 3% of the overall primary market, both with a high global diversification across the range of industries. Business interruption remains the most debated area of impact in the context of the COVID-19 crisis. We reiterate that most property policies require a physical trigger. And among those that offer coverage for nondamage business interruption, not all would cover pandemic.

In a number of markets, insurance had provided nondamage business interruption expansions that cover pandemic. However, which despite generally tied supplements, could add up to a material loss burden. We are monitoring the regulatory and legislative initiatives very closely. We echoed a deep concerns voiced by a number of our clients, peers and insurance regulators on the danger of potential retrospective changes to insurance contract wording.

Moving onto Life & Health Re. We had so far not seen a net impact on our business from increased mortality. For instance, mortality experience in the U.S. is in line with our expectations in the first quarter. We continue to monitor the trends here very closely, including any changes in less behavior and possible increases in disability claims. I would mention that a 5% mortality increase in insured mortality over a 1 year period would imply additional claims of approximately USD 400 million for Reinsurance and USD 15 million for Life Capital. The current scale of the impact of COVID on our book is still far from such a scenario.

A word on our 1-in-200 year pandemic stress. We previously disclosed excess mortality numbers this figure assumes in key countries, for instance, 200,000 in the U.S. Globally, our scenario assumes 14.5 million excess deaths. It should be noted, however, that this scenario is based on an influence of pandemic, which assumes a very different age fatality profile to COVID-19. The current virus disproportionately affects all the demographics with an average age of above 80 for fatalities, while 90% of our Life & Health Re portfolio covers individuals aged 60 or below.

Overall, there are still a number of key unknowns when it comes to assessing the ultimate potential impact of COVID-19 on our underwriting portfolio in 2020, the main ones being the severity and duration of the economic downturn as well as the outcome of litigation and legislative initiatives or out coverage for business interruption. However, we believe that the impact will be manageable and will represent an earnings event rather than a capital event for Swiss Re.

With that, let me hand over to Guido.

Guido Fürer  
*Group Chief Investment Officer & Member of Executive Committee*

Thank you, Edi. And good morning or good afternoon also from my side. Q1 saw significant COVID-related market turbulences across basically all asset classes. We experienced falling equity markets. We saw basically 2 out of the 5 biggest daily falls in Q1, but those were confronted to this widening credit spreads and bomb deals which were folding, all of which are damaging for insurance and reinsurers. However, as John mentioned, we put in place significant hedges in the early part of the quarter in anticipation of elevated volatility. These hedges helped us to mitigate negative impacts and led the gains of roughly USD 650 million in the first quarter, split evenly across equity and credit.

Ultimately, we experienced a net valuation loss of approximately USD 300 million in the first quarter. Overall, we report an annualized return on investment for the quarter of 3.2%, which would have been only 0.5% if you would exclude the benefit of the hedges. In addition, we had a \$80 million benefit on hedges for the U.K. equity market, which partly offset the negative impact of the Phoenix share price moving in our Life Capital result. As Reinsurance classified as health for sale, its investment portfolio is excluded from the return on investment calculation.

These hedges remain in place for the time being and we continue to manage them dynamically as the situation evolves, while retaining our cautious outlook. During the last few quarters, we carefully reviewed our investment portfolio for

issuers and sectors particularly sensitive to the ongoing crisis, resulting in a targeted reduction of credit exposures. This led to small realized losses on energy, special finance, travel and leisure bonds, as examples. Our ESG investment approach also contributed to the protective and high quality of our credit positioning. The group's impairment result was a modest USD 16 million in the quarter, reflecting the high quality of our credit portfolio. Given the downward trend in interest rates, our group running yields declined to 2.5% from 2.8% at the end of 2019.

With that, I hand over to Philippe who will take us through the Q&A.

**Philippe Brahin**

*Head Investor Relations and Head Governmental Affairs & Sustainability*

Thank you, Guido. And good day to all of you also from my side. So as usual, before we start our Q&A, I would like to remind you to please restrict yourselves to 2 questions and register again, if you have follow-up questions. So with that, operator, could we please take the first question?

# Question and Answer

## Operator

The first question comes from the line from Ivan Bokhmat from Barclays.

### Ivan Bokhmat

*Barclays Bank PLC, Research Division*

I've got 2. The first one is on your top line. Could you give us some big picture thoughts on how dependent it is on the economic activity and where do you see the biggest risks stemming from this downturn? And the second question, it's just relating to your SST ratio and capital sensitivities. Given the hedges that had been put in place, could you give us an updates of how the sensitivities may have changed and where should we expect the biggest reduction?

### Philippe Brahin

*Head Investor Relations and Head Governmental Affairs & Sustainability*

Maybe Edi, you take the first one, and John, the second one.

### Edouard Schmid

*Group Chief Underwriting Officer & Member of Executive Committee*

Yes, happy to comment a bit on the top line. And again, as for many other questions, it's still early days to come up with the views. What is clear as with the economic downturn, the lockdown in a number of lines of business, you would expect premium volumes to go down. If you think about motor lines, if you think about workers comp lines or related to the payroll, you would think about some of the sales in the Life business. So clearly there is expected to be an impact on the top line, but we would still expect the insurance industry to not be as impacted as, let's say, GDP overall. So quite an impact, but not as material for economies overall and quite dependent on the respective lines of business and end segments.

### John Robert Dacey

*Group CFO & Member of Executive Committee*

Edi, I might add that in the context of what will be some clear losses coming on both sides of the balance sheet for many of our reinsurance clients, one could imagine in the second half of the year and into 2019, an actual increased demand for reinsurance by those primary companies as they look to manage their own balance sheets and reduce potentially volatility of some of those earnings. So I think for well capitalized groups like Swiss Re, you could imagine the situation where the volatility in the marketplace actually creates increased demand for some of our capabilities and products in reinsurance.

With respect to the hedges and sensitivities, we've distributed also recently the sort of baseline that is used. To correctly point out, does not include the hedges. What I would say is that we don't expect these hedges to stay on forever. In fact, as Guido said, we'll look dynamically to understand when we can withdraw them when we feel that the economic conditions in the various markets have stabilized and/or likely to move forward in a sustainable positive direction.

As such, we've not provided additional sensitivities just because they would be temporary in nature and it would be potentially misleading to put them out there. What I can say is, at the moment we have protected the downside for equity values substantially. The credit hedges are more partial in the coverage. And there is undoubtedly some basis risks between the portfolio we have and the liquid hedges that we were able to find reasonable volumes and prices for.

On interest rates, generally I think we remain somewhat exposed with some modest adjustments to those sensitivities. But I think overall, we can say those sensitivities as we published are the outer bound of what you should expect over the next quarters. And depending on Guido's actions, we'll either come closer to them or stay much more conservative based on our view of the financial market volatilities.

### Philippe Brahin

*Head Investor Relations and Head Governmental Affairs & Sustainability*

All right. Thanks, Ivan for your questions.

## Operator

Copyright © 2020 S&P Global Market Intelligence, a division of S&P Global Inc. All Rights reserved.

[spglobal.com/marketintelligence](https://spglobal.com/marketintelligence)

The next question comes from Andrew Ritchie from Autonomous.

**Andrew James Ritchie**  
*Autonomous Research LLP*

Could I just ask to get a bit more color on the prior-year effect in P&C Re? I'm a bit confused why -- just to go through again, the premium adjustments and exactly what that is. Adjusting -- it's clearly not adjusting exposure. And you're saying all of the prior year was related to that or what else was the factor? And then I guess the other question. Do you expect -- I mean, John, you mentioned we could see increased demand and there's evidence of that already. I guess, a question for Edi. Do you expect mid-year renewals to already be affected by what's occurring in terms of slightly less capacity in the market and also increased demand?

**Edouard Schmid**  
*Group Chief Underwriting Officer & Member of Executive Committee*

So on the first one regarding the PYD. So for this quarter, indeed there was a bit more development on the premium line. I will also comment on the claims line later. But what happened a bit more than in other quarters that the premium that are coming through are not in line with our earlier assumptions. It's coming actually not from one specific part of the business. It's across markets, across lines of business, mainly from proportional contracts where we, in the end, rely on our cedents and therefore costs. And at this time, these forecasts tended to be on the optimistic side. So that explains why a bit more than normal, we had a more significant movement on the premium line.

There was also some slight negative development on the claims line, but very moderate. There were some pluses and minuses. We had some negative on U.K. motor and there was also some negative from U.S. liability. We had a couple of cedents that we're catching up what's there reporting on claims. But overall, it was quite a moderate quarter in terms of PYD. And I would also point out that on the Corporate Solutions side in Q1, the prior-year development was actually slightly positive, which is good news that the decisive reserving actions we took end of last year seemed to be holding up.

And the second one, Andrew, was around impacts on pricing already for the mid-year renewables. So I'm a bit cautious on speculating on prices. But clearly if you look at the industry overall already, we have started to see significant price momentum, as you know, in the commercial markets and more and more now also on the reinsurance side in areas where it was last affected.

We had very successful renewals in Japan as John pointed out, where we could achieve substantial premium increases. So I think with the impacts likely on the capital position on some primary companies with a bit more avoidance of risk in general, clearly the demand is expected to go up while the fee effect in the markets would impact supply on the other hand. So I would say it's quite a likely outlook that we see further price strengthening. We can also look just at the recent development in the ILS markets, the alternate capital markets where also spreads were widening a bit, so everything points in this direction. Yes, but it's too early to tell to what extent. But clearly, supply-demand equilibrium is shifting.

**John Robert Dacey**  
*Group CFO & Member of Executive Committee*

Maybe just one clarification on the first part. As Edi mentioned on premiums, there is no direct link to COVID-19 to this premium adjustment. I think most quarters we've got some movements. It just so happened in this first quarter of 2020 that there was an unusually mix of relatively large premium adjustments compared to the size of the claims adjustment that netted through.

**Philippe Brahin**  
*Head Investor Relations and Head Governmental Affairs & Sustainability*

Thanks, Andrew. Thanks for your questions.

**Operator**

[Operator Instructions] The next question comes from Paris Hadjiantonis from Exane BNP Paribas.

**Paris Hadjiantonis**  
*Exane BNP Paribas, Research Division*



Two questions from my side. The first one will be on nat cat. So basically, hard look at your nat cat premiums; these are up about 6% this year, obviously driven by pricing and your budget is also slightly up about less than a 6%. So I'm just wondering, are you actually increasing your nat exposures? Or are you passing most of the additional catastrophe risk that you're underwriting over to ACP or external retro? Then on COVID-19, I mean we know that giving precise estimates at this point in time is probably too difficult. But I was wondering if there are any developments or maybe exposures that cause concerns especially from a risk management perspective?

**Philippe Brahin**

*Head Investor Relations and Head Governmental Affairs & Sustainability*

Edi, back to you again.

**Edouard Schmid**

*Group Chief Underwriting Officer & Member of Executive Committee*

Yes. Thanks, Paris, for the questions. On the first one regarding our nat cat account, this is correct. If we just measure the nat calculated premium in P&C Re, that's up about 6% last year versus this year. That's in line with the strategy. We also explained last year at the Investors Day that we look at nat cat as an attractive pool. However, we have good client franchise and also the risk knowledge to underwrite this business in a good way.

But also back then, we said that our goal is to use our franchise and our risk knowledge to do underwrites. But also, we want our nat cat portfolio rather to be more diversified. So when it comes to do the concentration peaks like hurricane, we started to actually share more of the business with alternative capital partners. And that, in the end -- you already gave a bit of the answer -- explains why the budget is only going up by some 3% which actually means that we see the bit more out to our alternative capital partners, but then we increase on the gross side.

As you may have also observed, alternative capital market was a bit more stretched in recent times. But actually Swiss Re could maintain the support from its third party capital provider and we could even get some more supports which is to issue it, also few more kept on, so that we actually go into the upcoming hurricane season with a good hedged portfolio and the portfolio that in the end is more diversified.

And the second one was quite broad about the areas of concern around COVID. I mean, I've already indicated in earlier calls the areas where there's likely going to be increased claims on the rent cancellation. I think we covered that quite a bit. Obviously, credit and surety is something to watch quite closely. Obviously, that's a line that's closely linked to the economic development with the recessionary outlook and the likelihood of increased defaults.

But also -- and maybe there is a good example to just point out the uncertainties so you can expect recessionary impact and more defaults -- on the other hand, the government interventions are really also quite unprecedented. And if you think about specifically for credit and surety, in many markets there is government support for the SME sector. There's discussions even in some markets that the government actually is backing up the trade credit business because trade credit is important to keep the economies going.

So there's just a number of unprecedented factors at play that make it very difficult to forecast what's really going to happen. But our credit and surety book, to maybe explain better, we have 10% market share in reinsurance. We are not a leader as bigger ones. And of course, I think I mentioned it's less than 3% and it's a very diversified book of business. And we already -- actually because of the end of cycle situation, already reduced our exposure there. So credit and surety is an area. And then I think there's obviously many other areas where there are plusses, but obviously more minuses there. So leave it at that for the time.

**Operator**

The next question comes from Thomas Fossard from HSBC.

**Thomas Fossard**

*HSBC, Research Division*

Two questions for me. The first question will be, could you tell us if you have taken additional measures since COVID-19 crisis started, if you have taken any additional measures to protect your balance sheet? Actually, you indicated significant derisking offshore investment portfolio. I see that that was clear and that was explained by Guido. Now I was thinking on

every single part from investments. Have you taken additional measures in order to protect your book, I don't know, with additional protection assuming that in order to meet the effects?

The second question will be on CorSo. The first question would be the 13% price increase, for the momentum, is still keeping up well. But in light of the recessionary environment and in light of supporting and talking to your clients, how do you believe that certain percent is still achievable in the new environment? And also, due to this new environment, are you taking a pause to the cost reduction program at CorSo?

**Philippe Brahin**

*Head Investor Relations and Head Governmental Affairs & Sustainability*

Thanks. Maybe John for the first question and Edi on the CorSo.

**John Robert Dacey**

*Group CFO & Member of Executive Committee*

Sure, I might come back on the last. So in terms of protecting the balance sheet, I think that first and foremost these actions on the asset side have been a significant and, if I can say so, obviously effective. And we do see the negative impact that otherwise would have come through. On this side, obviously you have whether P&L relevant and then those items which are just relevant on the balance sheet. The one thing I would point out is that the book value of the company has held up extraordinarily well through the first quarter. If you compare book value per share on March 31 to where we were on December 31, the reduction is less than 4%. And that I think is indicative of how we've been able to manage the extraordinary actions that otherwise might have hit us for a potentially double-digit decline.

I think on the liability side, the smartest way to protect our balance sheet is to do smart underwriting. And once again, we're in a quarter where the COVID numbers are distracting us from speaking about the underlying. But let's remember that we made \$300 million in our Life & Health Re business in the quarter. We really are on track for the 2 estimated loss ratios; 97% in P&C Re and 105% in CorSo for the year. So I think the best thing we can do is make sure that, in spite of 14,000 people working from home, continue to deliver the kind of results that we had in the April 1 renewals to make sure that that business is going very well, while simultaneously managing the crisis of the pandemic and the associated fallout on economic activity from that.

So that's the -- where management is. There is a series of weekly and even in some cases, biweekly meeting that have been instituted to separate the active management of COVID-19 related issues from our day-to-day operations and those day-to-day operations proceed at pace with almost no interruptions.

**Edouard Schmid**

*Group Chief Underwriting Officer & Member of Executive Committee*

Yes. Maybe if I could just add bit of color on the liability side. Early on as to COVID crisis unfolded, we took a number of actions in terms of adjusting our underwriting appetite. In the end, this is a crisis still unfolding. So the picture you can have in mind is that of a burning house and obviously as an insurer, you need to be very careful not to provide coverage for things that are already foreseeable. So across many lines of business in P&C and Life & Health, we have tightened our under-appetite to not put undue risk on our balance sheet.

So for example, we have reduced the capacity for large lives it would put out there because there's really a risk of increased adverse selection or when it comes to a line like disability income that is linked to some extent to economic development recession. We also reduced the appetite and there's many examples in other areas. And so that's obviously an important dimension to protect our balance sheet. But as John said, it's equally important for those lines, those exposures that are not materially impacted by COVID, that our business, our underwriting, and everything continues as normal as possible.

And then on your second question was around the pricing dynamics in the commercial business. I would clearly see this to continue. I mean we have already started to see the movement. It was still quite slow. We know a year ago, in the beginning, was only 5%, and then over 2019 averaged CorSo could achieve 12%. And now in the first quarter, it's up to 13%. I think also relating to the comments earlier, just dynamics in the risk taking markets overall, it's what's happening, I think the only direction I think that this momentum is going to.

And I think the last one was on the cost side. John, you want to take that?

**John Robert Dacey**

*Group CFO & Member of Executive Committee*

Yes. So the restructuring at CorSo was laid out where removing about one-third of the business that was on the books at mid-year 2019. You start to see that show up in the premium earned in spite of the rate increases that we're getting. We've actually, I think, for the first quarter shown a reduction in earned premium because of the portfolios which have not renewed. In many cases, there were whole teams which were relieved with their responsibilities because we're not in the business. The good news is some of that -- a fair amount of that was done in 2019 before the crisis and so, many of those people were able to migrate to other carriers that were more convinced of future success in those lines. I think we'll continue to reshape CorSo into a strong performing company. That means following through on already-committed actions. I don't think we necessarily need to do more than that at this time.

**Operator**

The next question comes from Jonny Urwin from UBS.

**Jonathan Peter Phillip Urwin**

*UBS Investment Bank, Research Division*

Just 2 please. So firstly on business interruption, please could you comment on whether you're seeing reinsurance policy wordings broadly following the primary policy wordings and became so as kind of here, what will you think of the main risks on BI? So is there explicit or unintended exposures in policy wordings or is it the risk of retrospective legal challenge to coverage -- those comments are on your books specifically?

And then, I guess one, just thinking about the balance sheet and scope to grow gross loss, I mean do you think you have the balance sheet strength and the appetite to go after the capital intensive lines that could see more rates, given the likely reduction we're seeing in industry capital? Just being -- I suspect you'll say you've got the balance sheet, but I'm more interested in the appetite.

**Philippe Brahin**

*Head Investor Relations and Head Governmental Affairs & Sustainability*

Thanks, Jonny. We will start with Edi.

**Edouard Schmid**

*Group Chief Underwriting Officer & Member of Executive Committee*

Yes. Well, thanks, Johnny. The first one on business interruption, as mentioned in the introductory comments, that it's clearly the most debated area and obviously the main discussion first is happening on the primary side to what extent pandemic triggered business interruption is covered or not. We still remain of the view that most property policies, they actually require a physical damage trigger for a BI to be claimable, particularly the large limits on BI or these policies.

And then already there's a range of what you call nondamage BI extensions in several markets. And these you have to then put into different pockets so that shows where clearly pandemic is. It's excluded on the one extreme, but on the other extreme, there are a number of policies out there that clearly cover pandemic. And then there's a whole range in between where there's, for example, additional triggers that need to be met, so the policy would only pay if there is an outbreak of the infectious disease on the premise and then you need the closure by public authorities. So it's in this gray area where currently all our cedents are going through their portfolios to identify what is really in their portfolio.

So that that's really what's happening on the regional side and clearly there will be some areas where there will be legal disputes. I mean on the retrospective inclusion by legislation, I think commented in introduction, that's just a deeply concerning idea. Insurance really relies on the rule of law. And if we move down that track, clearly it would go beyond what the insurance industry is, if it's able to bear, and there I believe that reason will prevail. So that's more the situation on the original side.

And then on the reinsurance side, it really depends on the kind of contracts, proportional or non-proportional. And then there's some contracts, for example catastrophe contracts where clearly it's named perils, that there would be no exposure. But there's also contracts where it really follows the original policy wording. And then a question is then about aggregation of losses. But there we have also quite some elements in terms of event definitions, hours clauses. So there's

a lot of things that need to be sorted out. But that's just to give you a bit of color why that -- it takes a bit of time to have a clear assessment of the whole landscape around business interruption.

Maybe the second one, John, your take about our ability to asset [ legislature ]?

**John Robert Dacey**

*Group CFO & Member of Executive Committee*

Sure. And just so I understand it's the -- it is frustrating not to have clear estimates of what this looks like. But it just remind people that there's enormous uncertainty on the underlying health issues and nature of the pandemic. In our worldwide offices, we see some place is well organized as Singapore is, now looking at its third wave. And so to think that we're out of this first storm of the pandemic I think is absolutely premature than the subsequent economic cost to it and what is, in fact, clearly the responsibilities of insurance, primary insurance, and ultimately reinsurance remains highly speculative. And so I just caution everybody from trying to get ahead of the facts on this one.

With respect, Jonny, to your second question, yes, I think you asked about capital intensive covers. We do think we have got the balance sheet to be able to manage this. But I think the hurdles, as you imply, are probably higher, right? The -- we're paying a lot of attention to where long-term interest rates are compared to some of our European competitors. We probably have more interest in U.S. dollar rates and are paying a lot of attention to how far down long-term rates have moved. That's affected our pricing. And when we talk about the required price increases in the April 1 renewals, some of that came from more conservative modeling of the nat cat risk, but some of that, as in the January 1 renewals, came from a different view of long-term rates.

And so anything that we do in terms of increasing business going forward is going to require to be value creative in this new rate environment and to the degree that it involves longer tail business, those hurdles just become more and more impactful in what the required pricing would be.

**Operator**

The next question comes from Vinit Malhotra from Mediobanca.

**Vinit Malhotra**

*Mediobanca - Banca di credito finanziario S.p.A., Research Division*

So one topic left, which I don't know if it was addressed in the first few minutes. I missed it. Sorry. This is about the U.S. workers' compensation. Seeing some very wide ranging numbers from various bodies, like the NCCI or even in California, I mean could you help us understand where you are sitting on that? What are the risks for you, if any or if material? And any color would be very helpful.

**Edouard Schmid**

*Group Chief Underwriting Officer & Member of Executive Committee*

Yes. Thanks, Vinit, for the question on workers' comp. We only touched it briefly as one line of business that is likely impacted definitely on the premium line. So U.S. workers' comp -- I mean what you would expect that obviously with the lockdowns that the premium is going down. But you could also see that many people working from home, some of the more exposed jobs not being conducted for the time being. It could also be, let's say, a reduction in frequency. But on the other hand, there will likely be claims on certain types of jobs. In terms of the healthcare workers, other care workers, just what we can say our workers' comp folks does not have a significant parts of these more exposed types of jobs.

Also our workers' comp business is mainly proportional contracts in the U.S. And those would have our [ currents ] kept, so that the maximum exposure from this development should actually be quite limited. So for our specific situation, we do not expect a material impact from the workers' comp business. But on a more broader basis, again just reiterating what John was saying, it's still early in the crisis in how this is going to unfold, still has more open questions than things we can really answer.

**Operator**

Our next question comes from Vikram Gandhi from Societe Generale.

**Vikram Gandhi**

*Societe Generale Cross Asset Research*

Apologies if you have already answered this question, since I dropped out of the line. Now firstly, can you give us some color on the underlying exposures in the U.S. casualty, i.e. D&O, E&O, MedMal, general [ advocate ], et cetera? And what kind of really flows through the umbrella next as spokes, which are the lines that are particularly susceptible to adverse developments in the prevailing circumstances? That's question one. Secondly, given the [ firstly ] weak results at CorSo and the 141% descend SST, how should we think about the prospects of a potential capital injection in the unit?

**Edouard Schmid**

*Group Chief Underwriting Officer & Member of Executive Committee*

Yes. Thanks, Vik. On the first one regarding mode of casualty, lots of business in the U.S. workers' comp had just covered. That's just at D&O space you hinted. There is -- if you look into past, recessions are linked to financial market turbulence, so that could be a pickup in losses on the D&O side. Again in industry history accounts, that's not a material segment we support. And then there's a more broader liability space that will obviously you could picture, more lawsuits against employers and other areas. I mean if we just add something to this picture, we are pointing -- we've been pointing out for a long time that the U.S. liability space in a -- lot aggressive towards environment with social inflation. All the reasons why -- I think why we have taken a very cautious stomps on U.S. liability business.

On the CorSo side, as we mentioned in earlier calls, we have taken a very decisive pruning, exceeding the most exposed lines in U.S. liability. And also on reinsurance, we continue to be quite defensive on the U.S. liability lines, particularly those exposed to severity, so in the 1-1 renewals. But again, in one fold, we have actually reduced our exposures to U.S. liability. We measure now within the client portfolios the limits underlying exposed to severity. And for the larger corporate segment, we actually have on a year-on-year basis taken out some 20% off of exposure. So clearly there is a room for further litigation also out of this COVID. But again, as for other lines, a lot at this point would be speculation. I have to come up more to a firm view of how this is going to unfold.

**John Robert Dacey**

*Group CFO & Member of Executive Committee*

And your question on CorSo's capital, yes, I mean obviously it'd be better if CorSo was making money than losing money. I reiterate that the prior-year development was a modest positive for the CorSo for the quarter. So we believe that we'll have to weather the COVID-19 claims in Q1, and for the quarters, we'll evaluate the capital levels at the business unit accordingly and make some decisions. But I'd say here at the end of the first quarter, we don't see the need to do anything in particular.

**Operator**

[Operator Instructions] The next question is a follow up question from Thomas Fossard from HSBC.

**Thomas Fossard**

*HSBC, Research Division*

I just wanted to come back on the April 1 renewals, the plus 4% premium gross. Could you shed a bit of some light on split maybe on geographical basis, Asia versus U.S maybe? And also if you could split it differently by lines of business property versus specialty versus liability just to bear the stand? I mean how you shifted your book in -- at Q1? And the second question would be ready to gain through social claims inflation, U.S. social claims infection because it's been a big topic in Q3 and Q4 last year for the market. So then, you're completely disappearing from any price reductions or of core [indiscernible]. So -- and I guess that's on the line since claims trend as for you not stopped from one day to the other. So just if you could tell us a bit how things -- what you saw in terms of trends in terms of claims so far this year, in terms of maybe second derivative accelerational duration?

**Philippe Brahin**

*Head Investor Relations and Head Governmental Affairs & Sustainability*

Back to you, Edi.

**Edouard Schmid**

*Group Chief Underwriting Officer & Member of Executive Committee*

Back to me. The first one is a bit more color on our renewal account. So 4% growth across the board, obviously that has an element of the price increases. That is the most significant contributor at this time. We could achieve nominal price

increases year-to-date on what we renewed of 6%, which is significant across our book. As we also said actually on a risk-adjusted basis, this would be about flat. But still this is actually positive because it means that we could not only compensate for the more conservative loss specs. In for example, U.S. casualty, which is related to your second question, where we still see that this is a high possibility environment. So we needed to cost this more conservatively, so that loss assumption increases plus the significant adjustments we made to our typhoon flood modeling in Japan.

So these factors we could fully compensate by the normal increases we achieved. And in terms of the growth, it's also a bit linked to the fact that I just mentioned. So clearly in Japan, we could grow the total premium by about 20% in the nat cat space with the price increases. But also we deployed more capacity, given the beneficial outcomes we could achieve. But then linked to our increased capacity on the nat cat side, we could also access some additional business from clients in other lines of business. But a bit more broadly, I would still say that our trajectory as already explained in 1-1 is to shift the portfolio up a bit more to shorter duration. So we keep growing more on the property nat cat side and have a more cautious stance on the longer tail lines exposed to things like social inflation. And then obviously there's also the important point John made that in a much lower interest rate environment, obviously these longer tailed liability lines need to get even better in terms of underwriting profit to make sense, given that you cannot discount as much anymore.

So that's a bit of color around where the growth is coming from. And on the social inflation topically, that's not going away in the U.S. as we have commented earlier. We really think for the U.S. liability market to become sustainable that there needs to be more than just premium increases and limited auctions. That's clearly what's happening in the underlying business now. But what was this aggressive thought environment with this nuclear verdict, a lot of them are actually around commercial motor. If there is car accidents and bodily injury, then the court lawyers will go aggressively after some corporates and the jurors will then abort this huge noneconomic damages. And for that to become better, you will need to see some court reform at the state or at the federal level to become again more reasonable. And now you would add the developments around COVID in the U.S., so it is clearly an area where we would continue to underwrite with utmost caution.

**John Robert Dacey**

*Group CFO & Member of Executive Committee*

And maybe just one observation on the penultimate point of Edi. To the degree that motor frequency has materially reduced in all markets with lockdowns, you'll probably see some modest benefit also on some of this commercial motor caseload and associated large jury awards related to it. But there's clearly a very temporal issue that there's no reason to think there has been any structural change or improvement in that business.

**Philippe Brahin**

*Head Investor Relations and Head Governmental Affairs & Sustainability*

Well, thanks, Thomas, for your questions.

**Operator**

Our next question is a follow up question from Paris Hadjiantonis from Exane BNP.

**Paris Hadjiantonis**

*Exane BNP Paribas, Research Division*

So a couple of very small follow ups from my side. I guess the first one will be on Life Re. I understand there was a small clinical benefit for the quarter. I don't know whether you can give us some color and quantify that that. I think it was something to do with the recapture. And the other one is on the investment side. Obviously, quarter-to-date, we have seen a pronounced bounce back on the equity front. How should we be thinking about the benefit to Swiss Re from an accounting perspective given that you have put quite a lot of hedgers in place?

**Philippe Brahin**

*Head Investor Relations and Head Governmental Affairs & Sustainability*

Why don't we go to the second question first? So Guido can help us out.

Guido Fürer

*Group Chief Investment Officer & Member of Executive Committee*

Very happy to do so. Thanks, Paris, for the question. You will refer to the equity protection which we've put in place. And as John has mentioned, we will dynamically manage to deal with it not only for equity but also on credit. Now on equity, we have only option in place. That means the capital full [ upside ] is open. And as you know on the U.S. GAAP, both flows through the P&L out of the mark-to-market of the equity as well as of the hedges now. The fact that we have only downside protection doesn't take away the full upside potential. That's why the cover which we have seen quarter-to-date should be very helpful.

I think on the credit side, we have also a mixed set of different measures. Some are option related, some are index related. And that's why also there we kept some of the optionality open. Very important for us is the quality of the books. And as opposed on the equity as well as on the credit, and as John has mentioned, we actively do portfolio management. That's why we not only workers overlays, we take out some of the beta risk, but clearly all the massively improved quality of the portfolio. Over the last few quarters and they give you just one figure to give you a bit of a feeling. I think there's a good questioning about the fall of angel potential in our industry. And yes, we know under certain regulation, you don't get the capital benefit if it's outside of investment grades and talking about matching adjustments.

Swiss Re does not make use of that plus although we just saw what happened in the midst of the crisis related to Q1. The benchmark portfolios, they had a fallen angel in Q1 of 1% basically. Credits being non-investment grade from former investment grades. Swiss Re experienced through the same quarter just a 0.2%. That means 1/5 of the market. And also thanks to the hedge, I have to say in many of the exposed -- the COVID exposed tax, there are like leisure kind of consumer cyclicals, but also aviation. We are even net short. And that's why it's a very dynamic program. And I think we look at both. We look at the beta risk which we clearly address with the overlay program.

But in the long term and I also believe as John has alerted to, this crisis is not over in the short term. The economic damage is huge and some sectors will clearly be hammered not only over few weeks, but over a few quarters, if not years. And we recognize that very early. That's why we massively adjusted the portfolio position, started already last year. And to give you just one figure, in Q4 last year and in Q1 this year, we had \$7 billion of changes in the cover-bond portfolio. That's basically 25%. And of course, we went into the less exposed area and this gives you some idea how we protect the balance sheet. And again that we -- even if that crisis continues to do, we expect that we will serve relatively decent in this environment. But it's full of challenge. Thank you.

**John Robert Dacey**

*Group CFO & Member of Executive Committee*

Thank you, Guido. The first question you had, Paris, I think was related to the Life & Health Re. As we said, we had a strong technical result as well as a good investment return. Specifically, I think there was one not huge, but note -- of a size that's probably worth noting. We captured for some individual mortality business in Japan. Again just serving our clients well and working with them on the way that they like us to help manage their own risk. So nothing special there, ordinary business. And we do these kind of transactions on a routine basis.

**Philippe Brahin**

*Head Investor Relations and Head Governmental Affairs & Sustainability*

Okay. Paris, thank you for your follow up question. So we have actually come to the end of our Q&A. If you have any further questions, please contact members of the IR team. Thank you again for joining today. We wish you all to remain safe and healthy.

Operator, back to you.

**Operator**

Thank you for your participation. Ladies and gentlemen, you may now disconnect.

Copyright © 2020 by S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved.

These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable. No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content. THE CONTENT IS PROVIDED ON "AS IS" BASIS. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages. S&P Global Market Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence may provide index data. Direct investment in an index is not possible. Exposure to an asset class represented by an index is available through investable instruments based on that index. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain nonpublic information received in connection with each analytical process.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, [www.standardandpoors.com](http://www.standardandpoors.com) (free of charge), and [www.ratingsdirect.com](http://www.ratingsdirect.com) and [www.globalcreditportal.com](http://www.globalcreditportal.com) (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at [www.standardandpoors.com/usratingsfees](http://www.standardandpoors.com/usratingsfees).

© 2020 S&P Global Market Intelligence.